Missouri-based diagnostic provider C2N has struck a deal with diagnostic services provider Unilabs to expand access to its Precivity portfolio of Alzheimer’s blood tests in over 75 countries.
The US company will provide access to C2N’s blood tests across Europe and worldwide.
Go deeper with GlobalData
C2N’s blood tests aid in the detection of amyloid plaques and tau tangles in the brain – both of which are hallmarks of Alzheimer’s disease.
“Alzheimer’s disease is on the rise, making it essential to innovate by offering less invasive and more accessible diagnostic procedures for patients,” said Unilabs’ head of innovation Dr Rahul Chaudhary.
“This partnership will transform the diagnostic experience for patients with cognitive concerns while revolutionising early diagnosis, and research efforts, and positively impacting long-term outcomes.”
The partnership will also facilitate a technology transfer of C2N’s portfolio of Alzheimer’s blood biomarkers to establish a Unilabs testing network across Europe.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe initiative is conceived to ensure that Precivity testing can be performed at qualified healthcare institutions with the same quality, consistency and accuracy currently delivered at C2N’s central lab in St Louis, Missouri.
C2N recently published data in the Journal of the American Medical Association (JAMA) showing that its PrecivityAD2 blood test demonstrated a 90% accuracy in identifying Alzheimer’s in patients with memory loss, at a pre-defined, single binary cutoff compared to cerebrospinal fluid (CSF) analysis or amyloid PET analysis.
The data was also presented at the 2024 Alzheimer’s Association International Conference (AAIC), which ran until 1 August in Philadelphia, US.
During the conference, Eisai announced that patients undergoing continuous treatment with its anti-amyloid therapy Leqembi (lecanemab) for three years showed a slowing of Alzheimer’s disease progression.
The US Food and Drug Administration (FDA) converted Leqembi from an accelerated approval to a traditional approval for the treatment of Alzheimer’s disease last month.
According to GlobalData’s forecasts, Leqembi is anticipated to generate $6.1bn in 2030.
In March 2024, Eisai acquired a minority stake in C2N for $15m.
Elsewhere in the blood test market for Alzheimer’s, Biogen, Beckman Coulter and Fujirebio recently announced a partnership to identify and develop new blood-based biomarkers for Tau pathology.
